Peipei Shi

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 138 citations

Medicine, Oncology, Pharmacology +14

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Michael Crump, Sirpa Leppä, Luis Fayad et al. · Journal of Clinical Oncology · 2016 · 126 citations

Medicine, Oncology, Pharmacotherapy +13

SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer

Wen Gao, Dongli Liu, Haiyan Sun et al. · BMC Cancer · 2022 · 62 citations · Full text

Medicine, Cancer Biology, Oncology +17

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Jonathan W. Goldman, Peipei Shi, Martin Reck et al. · Clinical Lung Cancer · 2015 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Comparison of Real-Time Intraoperative Ultrasound-Based Dosimetry With Postoperative Computed Tomography-Based Dosimetry for Prostate Brachytherapy

Subir Nag, Peipei Shi, Bingren Liu et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 30 citations

Medicine, Radiation Oncology, Urology +16